|
|
Post by itellthefuture777 on Oct 3, 2017 11:32:20 GMT -5
Al Mann Said-"Some of you may recall a somewhat parallel story regarding my experience in MiniMed, which had protocol which had pioneered in insulin pumps and continuous glucose sensors. After some negative publicity by the serious problem with another company's pumps, the 3 major companies competing for that market all dropped out. Our stock was then priced at $1.75 per share. Later, Medtronic acquired MiniMed for a split-adjusted $192 per share. The story for MannKind has been similar with the low stock value. I am not suggesting an ultimate future gain by a factor of over 100 for MannKind, but I do remain very optimistic about the value of AFREZZA as well as several other product opportunities at MannKind. While the financial consequences of this past year have been costly, the company now has the resources to bridge our current needs and enable us to prepare for the future."
(That statement was made pre-split so that would be in todays stock 5x 100x that he isn't saying will happen but remains optimistic about) hmm..nice.. mind blowing
|
|
|
|
Post by itellthefuture777 on Oct 3, 2017 11:40:13 GMT -5
Al also said-"In early Type 2, a variety of alternative antiglycemic drugs are used today and these products are viable largely because of the deficiencies of current insulin products. But it is insulin that the body needs for glucose metabolism. Even with the limitations of current insulin products, there is increasing pressure to move patients much sooner to exogenous insulin. The alternative antiglycemic products are intended simply to supplement endogenous pancreatic insulin more effectively. Some of them are directed to increasing pancreatic output, likely contributing to early-year beta cell burnout. Other products have tested lower resistance to insulin to inhibit hepatic glucose release or to slow digestion, but all of these drugs have limited efficacy and side effects that can be significant in some patients and the long-term safety for many of them may still be in doubt. Moreover, none of these antiglycemics, I believe, does slow progression of the disease so that, after 8 to 12 years, patients using those drugs typically move on to insulins.
Another issue is that many of the newer, more advanced antiglycemic agents are very expensive. If only there were a physiologic ultra-fast-acting insulin that would reduce postprandial hyperglycemia to within normal guidelines without the risk of hypoglycemia or weight gain and without the complexity of titration or the need for multiple daily measurements of glucose. Such a prandial insulin would far better deal with postprandial excursions throughout the entire spectrum of diabetes. Moreover, key opinion leaders assert that, by reducing pancreatic and hepatic stress, such an insulin would slow and perhaps even stop progression of Type 2 diabetes and prediabetes. Surely, that would seem to offer a far better solution than those alternative drugs. Moreover, a therapy that does not require the inconvenience and discomfort of multiple daily injections, would certainly be more patient-friendly.
AFREZZA has been shown in over 50 clinical trials to mimic endogenous insulin kinetics and this should enable this insulin to more effectively and more safely address the objectives of providing improved glycemic control. A product such as AFREZZA would be especially appealing to children and should ease the issues about treatment in the classroom. Because of the FDA's aversion about risk in this young population, the initial label for AFREZZA will be restricted to patients 18 years and older. The age -- asked us [ph] to submit a post-approval Phase IV protocol for a trial in children. We responded with a proposed study in children ages 12 to 18. Interestingly, FDA directed us to include children down to age 4."
|
|
|
|
Post by mytakeonit on Oct 3, 2017 12:35:15 GMT -5
|
|
|
|
Post by itellthefuture777 on Oct 4, 2017 8:58:18 GMT -5
Superior Insulin..faster then FAISP of Novo Nordisk. in and out! Plus Mannkind has tech..anyone with tech is worth another 20%...on top their valuation...which for this stock..is north! Up!
|
|
|
|
Post by straightly on Oct 6, 2017 0:57:15 GMT -5
Al Mann Said-"Some of you may recall a somewhat parallel story regarding my experience in MiniMed, which had protocol which had pioneered in insulin pumps and continuous glucose sensors. After some negative publicity by the serious problem with another company's pumps, the 3 major companies competing for that market all dropped out. Our stock was then priced at $1.75 per share. Later, Medtronic acquired MiniMed for a split-adjusted $192 per share. The story for MannKind has been similar with the low stock value. I am not suggesting an ultimate future gain by a factor of over 100 for MannKind, but I do remain very optimistic about the value of AFREZZA as well as several other product opportunities at MannKind. While the financial consequences of this past year have been costly, the company now has the resources to bridge our current needs and enable us to prepare for the future." (That statement was made pre-split so that would be in todays stock 5x 100x that he isn't saying will happen but remains optimistic about) hmm..nice.. mind blowing While we are having fun speculating how Mike have to address our cash issue, I would not be surprised if Al has already set up financing to carry us through that. Matt should be a participant in that. Just wondering. But with this week's stock up swing, Mike should have even more options. We should know before the year end, probably even as soon as after 10/31 when Deerfield's payment becomes due, unless we get another postponement. |
|
|
|
Post by itellthefuture777 on Oct 6, 2017 6:38:49 GMT -5
Al Mann Said-"Some of you may recall a somewhat parallel story regarding my experience in MiniMed, which had protocol which had pioneered in insulin pumps and continuous glucose sensors. After some negative publicity by the serious problem with another company's pumps, the 3 major companies competing for that market all dropped out. Our stock was then priced at $1.75 per share. Later, Medtronic acquired MiniMed for a split-adjusted $192 per share. The story for MannKind has been similar with the low stock value. I am not suggesting an ultimate future gain by a factor of over 100 for MannKind, but I do remain very optimistic about the value of AFREZZA as well as several other product opportunities at MannKind. While the financial consequences of this past year have been costly, the company now has the resources to bridge our current needs and enable us to prepare for the future." (That statement was made pre-split so that would be in todays stock 5x 100x that he isn't saying will happen but remains optimistic about) hmm..nice.. mind blowing While we are having fun speculating how Mike have to address our cash issue, I would not be surprised if Al has already set up financing to carry us through that. Matt should be a participant in that. Just wondering. But with this week's stock up swing, Mike should have even more options. We should know before the year end, probably even as soon as after 10/31 when Deerfield's payment becomes due, unless we get another postponement. Faith in Phython Mike...team.and the product. |
|
|
|
Post by itellthefuture777 on Oct 6, 2017 12:35:41 GMT -5
Al..chose Mike..show us the power Mike!
|
|
